الإحصائيات الأساسية
| CIK | 792641 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Brilliant Acquisition Corporation
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| August 31, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 000-15266 Bio-Reference Laboratories, Inc. (Exact name of registrant as spe |
|
| August 20, 2015 |
Exhibit 10.1 FIFTEENTH AMENDMENT TO LOAN DOCUMENTS THIS FIFTEENTH AMENDMENT TO LOAN DOCUMENTS (this ?Amendment?) is made as of August 18, 2015, and is by and among Bio-Reference Laboratories, Inc. (?BRLI?), and GeneDX, Inc. (formerly known as BRLI No. 2 Acquisition Corp.), which conducts business as GeneDx (referred to herein from time to time as ?GeneDx? and a ?Subsidiary Party?) (BRLI and the Su |
|
| August 20, 2015 |
BIO-REFERENCE LABORATORIES, INC. ARTICLE I EX-3.2 3 d82627dex32.htm EX-3.2 Exhibit 3.2 BIO-REFERENCE LABORATORIES, INC. BY-LAWS ARTICLE I Offices The registered office of the Corporation shall be located at 830 Bear Tavern Road, West Trenton, County of Mercer, State of New Jersey. The Corporation may also have offices at such other places, both within and without the State of New Jersey, as may from time to time be designated by the Board |
|
| August 20, 2015 |
As filed with the Securities and Exchange Commission on August 20, 2015 As filed with the Securities and Exchange Commission on August 20, 2015 Registration No. |
|
| August 20, 2015 |
AMENDED AND RESTATED BIO-REFERENCE LABORATORIES, INC. EX-3.1 2 d82627dex31.htm EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BIO-REFERENCE LABORATORIES, INC. 1. Name: Bio-Reference Laboratories, Inc. 2. Registered Agent: Corporation Service Company 3. Registered Office: 830 Bear Tavern Road West Trenton, New Jersey 08628 4. Business Purpose: To engage in any activity within the purpose for which corporations may be organized |
|
| August 20, 2015 |
8-K 1 d82627d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2015 Bio-Reference Laboratories, Inc. (Exact name of registrant as specified in its charter) New Jersey 0-15266 22-2405059 (State or other juri |
|
| August 19, 2015 |
425 1 d23500d425.htm 425 Filed pursuant to Rule 425 under the Securities Act of 1933, as amended Deemed filed under Rule 14a-6(b) under the Securities Exchange Act of 1934, as amended Filer: OPKO Health, Inc. Commission File No.: 000-33528 Subject Company: Bio-Reference Laboratories, Inc. Commission File No. for Registration Statement on Form S-4 filed by OPKO Health, Inc.: 333-205480 OPKO Lab Sig |
|
| August 10, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 10, 2015 Bio-Reference Laboratories, Inc. |
|
| August 6, 2015 |
Filed pursuant to Rule 425 under the Securities Act of 1933, as amended Deemed filed under Rule 14a-6(b) under the Securities Exchange Act of 1934, as amended Filer: OPKO Health, Inc. |
|
| July 30, 2015 |
425 Filed pursuant to Rule 425 under the Securities Act of 1933, as amended Deemed filed under Rule 14a-6(b) under the Securities Exchange Act of 1934, as amended Filer: OPKO Health, Inc. |
|
| July 20, 2015 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, For Use of the Commission Only (as p |
|
| July 2, 2015 |
EX-99.1 Exhibit 99.1 OPKO and Bio-Reference Laboratories Announce Early Termination of the Waiting Period for Planned Acquisition MIAMI ?July 2, 2015?OPKO Health, Inc. (OPK) and Bio-Reference Laboratories, Inc. (BRLI), today announced that early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the ?HSR Act?) has been granted, effective July 1, 2015, |
|
| July 2, 2015 |
Opko Health FORM 8-K (Prospectus) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2015 OPKO Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33528 75-2402409 (State or other jurisdiction of incorporation) (Commission |
|
| July 2, 2015 |
Filing pursuant to Rule 425 under the Securities Act of 1933, as amended Deemed filed under Rule 14a-12 under the Securities Exchange Act of 1934, as amended Filer: Bio-Reference Laboratories, Inc. |
|
| June 18, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2015 OPKO Health, Inc. |
|
| June 18, 2015 |
EX-99.2 June 2015 1 Exhibit 99.2 BioReference Laboratories Snapshot 2 Division Key Products Markets Physician Offices, Health Facilities, Correctional Facilities Flow Cytometry, IHC, FISH, ISH, Microarray, Morphology Hematologists, Oncologists, Hospital Pathologists Obstetricians, Gynecologists, Maternal-Fetal Medicine NextGen & Sanger Sequencing, Array Comparative Genomic Hybridization (aCGH) Gen |
|
| June 18, 2015 |
EX-99.3 General Overview 18 June 2015 Exhibit 99.3 Our Vision We are a leading specialty pharmaceutical company To be the leading developer and supplier of highly potent pharmaceutical products for global markets Click above to view EirGen?s expanded facility Ireland: Fact Sheet Waterford Cork Dublin ? Population 4.2 million ? Largest Exporter of Pharmaceuticals in the World, 8 th largest producer |
|
| June 18, 2015 |
EX-99.1 2 d944813dex991.htm EX-99.1 Exhibit 99.1 Exhibit 99.1 Confidential Update on Rayaldee Capsules June 18, 2015 Cautionary Statement This presentation contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” |
|
| June 11, 2015 |
Filed pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Filer: OPKO Health, Inc. |
|
| June 11, 2015 |
EX-99.1 2 dp57061ex9901.htm EXHIBIT 99.1 Exhibit 99.1 EDITED TRANSCRIPT OKPO Health, Inc. and Bio-Reference Laboratories, Inc. Joint Conference Call EVENT DATE/TIME: June 11, 2015 /8:30 a.m. EDT C O R P O R A T E P A R T I C I P A N T S Dr. Phillip Frost, Chief Executive Officer and Chairman, OPKO Health Dr. Marc Grodman, President, Chief Executive Officer and Chairman, Bio-Reference Laboratories |
|
| June 11, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 11, 2015 Bio-Reference Laboratories, Inc. |
|
| June 10, 2015 |
Opko Health FORM 8-K (Prospectus) FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2015 OPKO Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33528 75-2402409 (State or other jurisdiction of incorporation) (Commissio |
|
| June 10, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 10, 2015 Bio-Reference Laboratories, Inc. |
|
| June 10, 2015 |
EX-99.1 Exhibit 99.1 Investor Presentation June 2015 Important Information for Investors and Shareholders This communication does not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities or a solicitation of any vote or approval. This communication relates to a proposed business combination between Bio-Reference Laboratories, Inc. (?Bio-Reference Laborat |
|
| June 10, 2015 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 10, 2015 Bio-Reference Laboratories, Inc. |
|
| June 10, 2015 |
Investor Presentation June 2015 Exhibit 99.1 Investor Presentation June 2015 Important Information for Investors and Shareholders This communication does not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities or a solicitation of any vote or approval. This communication relates to a proposed business combination between Bio - Reference Laboratories, Inc. (?Bio - Reference Laboratorie |
|
| June 10, 2015 |
Investor Presentation June 2015 EX-99.1 2 dp57048ex9901.htm EXHIBIT 99.1 Exhibit 99.1 Investor Presentation June 2015 Important Information for Investors and Shareholders This communication does not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities or a solicitation of any vote or approval. This communication relates to a proposed business combination between Bio - Reference Laborat |
|
| June 9, 2015 |
Fourteenth Amendment to Loan Documents Exhibit 10.1 Fourteenth Amendment to Loan Documents THIS FOURTEENTH AMENDMENT TO LOAN DOCUMENTS (this “Amendment”) is made as of May 5, 2015, and is by and among Bio-Reference Laboratories, Inc. (“BRLI”), and GeneDX, Inc. (formerly known as BRLI No. 2 Acquisition Corp.), which conducts business as GeneDx (referred to herein from time to time as “GeneDx” and a “Subsidiary Party”) (BRLI and the Subs |
|
| June 9, 2015 |
OPKO and Bio-Reference Laboratories To Hold Joint Conference Call to Discuss Merger EX-99.2 Exhibit 99.2 OPKO and Bio-Reference Laboratories To Hold Joint Conference Call to Discuss Merger MIAMI ? June 8, 2015 ? OPKO Health, Inc. (NYSE:OPK) and Bio-Reference Laboratories, Inc. (NASDAQ: BRLI) will host a joint conference call and webcast at 8:30 a.m. ET on Thursday, June 11, 2015, to discuss the previously announced entry into a merger agreement for OPKO to acquire Bio-Reference L |
|
| June 9, 2015 |
EX-99.1 Exhibit 99.1 FOR: BIO-REFERENCE LABORATORIES, INC. CONTACT: Tara Mackay Investor Relations Coordinator (201) 791-2600 (201) 791-1941 (fax) [email protected] FINAL - FOR IMMEDIATE RELEASE BIO-REFERENCE LABORATORIES, INC. REPORTS SOLID REVENUES AND EARNINGS FOR Q2FY15 Merger with OPKO Health, Inc. to create a bold new future for the Company ELMWOOD PARK, NJ (June 8, 2015) Bio-Referenc |
|
| June 9, 2015 |
BRLI / Bio-Reference Labs 10-Q - Quarterly Report - 10-Q 10-Q 1 a15-7384110q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended April 30, 2015 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from |
|
| June 9, 2015 |
Exhibit 10.3 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) dated as of June 3, 2015, among Bio-Reference Laboratories, Inc., a New Jersey corporation with its principal place of business at 481 Edward H. Ross Drive, Elmwood Park, New Jersey 07407 (the “Company”), OPKO Health, Inc., a Delaware corporation with its principal place of business at 4400 Biscayne Boulevard, Miami, Fl |
|
| June 9, 2015 |
THIRTEENTH AMENDED AND RESTATED SECURED REVOLVING NOTE (PNC Bank, National Association) Exhibit 10.2 THIRTEENTH AMENDED AND RESTATED SECURED REVOLVING NOTE (PNC Bank, National Association) $120,000,000.00 May 5, 2015 FOR VALUE RECEIVED, BIO-REFERENCE LABORATORIES, INC., a New Jersey corporation with an address at 481 Edward H. Ross Drive, Elmwood Park, New Jersey 07497 and its Subsidiary or Subsidiaries party hereto (collectively, jointly and severally the “Borrowers”), promise to pa |
|
| June 9, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2015 OPKO Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33528 75-2402409 (State or other jurisdiction of incorporation) (Commission File Num |
|
| June 8, 2015 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 8, 2015 Bio-Reference Laboratories, Inc. |
|
| June 8, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 8, 2015 Bio-Reference Laboratories, Inc. |
|
| June 8, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 dp569528k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 8, 2015 Bio-Reference Laboratories, Inc. (Exact Name of Registrant as Specified in Charter) New Jersey 0-15266 22-2405059 (State or Other Jurisdiction |
|
| June 8, 2015 |
OPKO and Bio-Reference Laboratories To Hold Joint Conference Call to Discuss Merger Exhibit 99.1 FOR: BIO-REFERENCE LABORATORIES, INC. CONTACT: Tara Mackay Investor Relations Coordinator (201) 791-2600 (201) 791-1941 (fax) [email protected] OPKO and Bio-Reference Laboratories To Hold Joint Conference Call to Discuss Merger MIAMI-(BUSINESS WIRE)-Jun. 8, 2015- OPKO Health, Inc. (NYSE:OPK) and Bio-Reference Laboratories, Inc. (NASDAQ: BRLI) will host a joint conference call a |
|
| June 8, 2015 |
OPKO and Bio-Reference Laboratories To Hold Joint Conference Call to Discuss Merger EX-99.1 2 dp56961ex9901.htm EXHBIT 99.1 Exhibit 99.1 FOR: BIO-REFERENCE LABORATORIES, INC. CONTACT: Tara Mackay Investor Relations Coordinator (201) 791-2600 (201) 791-1941 (fax) [email protected] OPKO and Bio-Reference Laboratories To Hold Joint Conference Call to Discuss Merger MIAMI-(BUSINESS WIRE)-Jun. 8, 2015- OPKO Health, Inc. (NYSE:OPK) and Bio-Reference Laboratories, Inc. (NASDAQ: B |
|
| June 8, 2015 |
Exhibit 99.1 FOR: FOR: BIO-REFERENCE LABORATORIES, INC. CONTACT: Tara Mackay Investor Relations Coordinator (201) 791-2600 (201) 791-1941 (fax) [email protected] FINAL - FOR IMMEDIATE RELEASE BIO-REFERENCE LABORATORIES, INC. REPORTS SOLID REVENUES AND EARNINGS FOR Q2FY15 - - - Merger with OPKO Health, Inc. to create a bold new future for the Company ELMWOOD PARK, NJ (June 8, 2015) Bio-Refer |
|
| June 4, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 3, 2015 Bio-Reference Laboratories, Inc. |
|
| June 4, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2015 OPKO Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33528 75-2402409 (State or other jurisdiction of incorporation) (Commission File Num |
|
| June 4, 2015 |
EX-10.2 4 dp56888ex-1002.htm EXHIBIT 10.2 Exhibit 10.2 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) dated as of June 3, 2015, between Bio-Reference Laboratories, Inc., a New Jersey corporation with its principal place of business at 481 Edward H. Ross Drive, Elmwood Park, New Jersey 07407 (the “Company”) and Nicholas Papazicos, (the “Employee”), effective immediately prior to |
|
| June 4, 2015 |
EX-2.1 2 d937919dex21.htm EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER BY AND AMONG OPKO HEALTH, INC., BAMBOO ACQUISITION, INC. AND BIO-REFERENCE LABORATORIES, INC. Dated as of June 3, 2015 TABLE OF CONTENTS Page Article 1 Transactions and Terms of Merger 2 1.1 Merger 2 1.2 Time and Place of Closing 2 1.3 Effective Time 2 1.4 Charter and Bylaws 3 1.5 Directors and Officers 3 1.6 Conversion of S |
|
| June 4, 2015 |
Exhibit 10.2 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) dated as of June 3, 2015, between Bio-Reference Laboratories, Inc., a New Jersey corporation with its principal place of business at 481 Edward H. Ross Drive, Elmwood Park, New Jersey 07407 (the ?Company?) and Nicholas Papazicos, (the ?Employee?), effective immediately prior to the Effective Time (as defined in the Agre |
|
| June 4, 2015 |
EX-2.1 2 dp56888ex-0201.htm EXHIBIT 2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER BY AND AMONG OPKO HEALTH, INC., BAMBOO ACQUISITION, INC. AND BIO-REFERENCE LABORATORIES, INC. Dated as of June 3, 2015 TABLE OF CONTENTS Page Article 1 Transactions and Terms of Merger 2 1.1 Merger 2 1.2 Time and Place of Closing 2 1.3 Effective Time 2 1.4 Charter and Bylaws 3 1.5 Directors and Officers 3 1.6 Conversi |
|
| June 4, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 3, 2015 Bio-Reference Laboratories, Inc. |
|
| June 4, 2015 |
OPKO Health to Acquire Bio-Reference Laboratories EX-99.1 3 d937919dex991.htm EX-99.1 EXHIBIT 99.1 OPKO Health to Acquire Bio-Reference Laboratories - Complementary in-depth expertise in diagnostics business with state of the art experience in use of genomic data for personalized therapy - Acquisition provides national sales force to accelerate adoption of OPKO’s 4Kscore™ test for aggressive prostate cancer June 4, 2015, OPKO HEALTH, INC. (NYSE: |
|
| June 4, 2015 |
EX-2.1 2 dp56888ex-0201.htm EXHIBIT 2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER BY AND AMONG OPKO HEALTH, INC., BAMBOO ACQUISITION, INC. AND BIO-REFERENCE LABORATORIES, INC. Dated as of June 3, 2015 TABLE OF CONTENTS Page Article 1 Transactions and Terms of Merger 2 1.1 Merger 2 1.2 Time and Place of Closing 2 1.3 Effective Time 2 1.4 Charter and Bylaws 3 1.5 Directors and Officers 3 1.6 Conversi |
|
| June 4, 2015 |
EX-10.1 3 dp56888ex-1001.htm EXHIBIT 10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) dated as of June 3, 2015, among Bio-Reference Laboratories, Inc., a New Jersey corporation with its principal place of business at 481 Edward H. Ross Drive, Elmwood Park, New Jersey 07407 (the “Company”), OPKO Health, Inc., a Delaware corporation with its principal place of busi |
|
| June 4, 2015 |
Filing pursuant to Rule 425 under the Filing pursuant to Rule 425 under the Securities Act of 1933, as amended Deemed filed under Rule 14a-12 under the Securities Exchange Act of 1934, as amended Filer: Bio-Reference Laboratories, Inc. |
|
| June 4, 2015 |
OPKO Health to Acquire Bio-Reference Laboratories Ehxibit 99.1 OPKO Health to Acquire Bio-Reference Laboratories - Complementary in-depth expertise in diagnostics business with state of the art experience in use of genomic data for personalized therapy - Acquisition provides national sales force to accelerate adoption of OPKO?s 4Kscore? test for aggressive prostate cancer June 4, 2015, OPKO HEALTH, INC. (NYSE: OPK) and Bio-Reference Laboratories, |
|
| June 4, 2015 |
EX-10.1 3 dp56888ex-1001.htm EXHIBIT 10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) dated as of June 3, 2015, among Bio-Reference Laboratories, Inc., a New Jersey corporation with its principal place of business at 481 Edward H. Ross Drive, Elmwood Park, New Jersey 07407 (the “Company”), OPKO Health, Inc., a Delaware corporation with its principal place of busi |
|
| June 4, 2015 |
OPKO Health to Acquire Bio-Reference Laboratories EX-99.1 5 dp56888ex-9901.htm EXHIBIT 99.1 Ehxibit 99.1 OPKO Health to Acquire Bio-Reference Laboratories - Complementary in-depth expertise in diagnostics business with state of the art experience in use of genomic data for personalized therapy - Acquisition provides national sales force to accelerate adoption of OPKO’s 4Kscore™ test for aggressive prostate cancer June 4, 2015, OPKO HEALTH, INC. ( |
|
| May 20, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 14, 2015 Bio-Reference Laboratories, Inc. (Exact name of registrant as specified in its charter) New Jersey 0-15266 22-2405059 (State or other jurisdiction (Commission (IRS Employe |
|
| April 29, 2015 |
FIRST EXTENSION OF EMPLOYMENT AGREEMENT EX-10.1 2 a15-102811ex10d1.htm EX-10.1 Exhibit 10.1 FIRST EXTENSION OF EMPLOYMENT AGREEMENT This First Extension of Employment Agreement (the “First Extension” dated April 23, 2015, and by vote of the Compensation Committee of the Board of Directors of Bio-Reference Laboratories, Inc., to be retroactive to and effective January 29, 2015, is made between Bio-Reference Laboratories, Inc., a New Jers |
|
| April 29, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 23, 2015 Bio-Reference Laboratories, Inc. (Exact name of registrant as specified in its charter) New Jersey 0-15266 22-2405059 (State or other jurisdiction (Commission (IRS Emplo |
|
| March 13, 2015 |
8-K 1 a15-679418k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 9, 2015 Bio-Reference Laboratories, Inc. (Exact name of registrant as specified in its charter) New Jersey 0-15266 22-2405059 (State or other jurisdicti |
|
| March 9, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q 10-Q 1 a15-6163110q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended January 31, 2015 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fr |
|
| March 5, 2015 |
Exhibit 99.1 FOR: BIO-REFERENCE LABORATORIES, INC. CONTACT: Tara Mackay, Investor Relations (201) 791-2600 (201) 791-1941 (fax) [email protected] FOR IMMEDIATE RELEASE BIO-REFERENCE LABORATORIES, INC. REPORTS OVER 15% INCREASE IN REVENUE; NET INCOME UP OVER 100%, YEAR OVER YEAR - - - Improvement in Cash Flow and Increase in Revenue per Patient, 3 cents/share related to increase in legal exp |
|
| March 5, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 5, 2015 Bio-Reference Laboratories, Inc. (Exact name of registrant as specified in its charter) New Jersey 0-15266 22-2405059 (State or other jurisdiction (Commission (IRS Employ |
|
| March 5, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 3, 2015 Bio-Reference Laboratories, Inc. (Exact name of registrant as specified in its charter) New Jersey 0-15266 22-2405059 (State or other jurisdiction (Commission (IRS Employ |
|
| February 12, 2015 |
SC 13G/A 1 manulifesc13ga.htm AMENDMENT TO SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Bio-Reference Laboratories, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09057G602 (CUSIP Number) December 31, 2014 (Date of Event Which Requir |
|
| February 11, 2015 |
BRLI / Bio-Reference Labs / VANGUARD GROUP INC Passive Investment SC 13G/A 1 bioreferencelabsinc.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2 )* Name of issuer: Bio-Reference Laboratories Inc Title of Class of Securities: Common Stock CUSIP Number: 09057G602 Date of Event Which Requires Filing of this Statement: December 31, 2014 Check the appropriate box to designate the r |
|
| February 4, 2015 |
BRLI / Bio-Reference Labs / RBC Global Asset Management (U.S.) - SCHEDULE 13G Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Bio-Reference Laboratories, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09057G602 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| January 13, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [Mark One] x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-15266 BIO-REFERENCE LAB |
|
| January 13, 2015 |
Exhibit 21 The following are the Company?s wholly-owned subsidiaries: Jurisdiction of Incorporation Name under which it Conducts of Conducted Business CareEvolve. |
|
| January 13, 2015 |
2015 Senior Management Incentive Bonus Plan EX-10.5 2 a14-218581ex10d5.htm EX-10.5 Exhibit 10.5 2015 Senior Management Incentive Bonus Plan Participants: Marc D. Grodman, MD, CEO Wendy Chung, CSO Howard Dubinett, COO Charles T. Todd, Sr. VP Marketing & Sales Amar Kamath, VP Marketing Gary Reeves, VP, Women’s Health Scott Montgomery, VP, Clinical Warren Erdmann, SVP Operations Nick Cetani, VP Laboratory Director Ron Rayot, VP Chris Smith, VP |
|
| January 13, 2015 |
CODE OF ETHICS FOR EXECUTIVE OFFICERS AND KEY FINANCIAL AND ACCOUNTING PERSONNEL Exhibit 14 CODE OF ETHICS FOR EXECUTIVE OFFICERS AND KEY FINANCIAL AND ACCOUNTING PERSONNEL This code of ethics applies to Bio-Reference Laboratories, Inc. |
|
| December 18, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a14-2643418k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 18, 2014 Bio-Reference Laboratories, Inc. (Exact name of registrant as specified in its charter) New Jersey 0-15266 22-2405059 (State or other juris |
|
| December 18, 2014 |
Exhibit 99.1 FOR: BIO-REFERENCE LABORATORIES, INC. CONTACT: Tara Mackay Investor Relations Coordinator (201) 791-2600 (201) 791-1941 (fax) [email protected] FOR IMMEDIATE RELEASE BIOREFERENCE LABORATORIES, INC. ANNOUNCES QUARTERLY AND YEARLY RECORD REVENUES, NET INCOME AND PATIENT VOLUMES - - - The Company’s fourth quarter financial results showed substantial year over year improvement ELMW |
|
| November 21, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 17, 2014 Bio-Reference Laboratories, Inc. (Exact name of registrant as specified in its charter) New Jersey 0-15266 22-2405059 (State or other jurisdiction (Commission (IRS Em |
|
| September 4, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| August 27, 2014 |
EX-99.1 2 a14-201141ex99d1.htm EX-99.1 Exhibit 99.1 FOR: BIOREFERENCE LABORATORIES, INC. CONTACT: Tara Mackay Investor Relations Coordinator (201) 791-2600 (201) 791-1941 (fax) [email protected] FOR IMMEDIATE RELEASE BIOREFERENCE LABORATORIES, INC. REPORTS RECORD QUARTERLY REVENUES AND PATIENT VOLUMES FOR THIRD QUARTER FY2014 - - - Revenues increase 20% on a YoY basis and patient count incr |
|
| August 27, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 27, 2014 Bio-Reference Laboratories, Inc. (Exact name of registrant as specified in its charter) New Jersey 0-15266 22-2405059 (State or other jurisdiction (Commission (IRS Empl |
|
| July 24, 2014 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 10, 2014 Bio-Reference Laboratories, Inc. (Exact name of registrant as specified in its charter) New Jersey 0-15266 22-2405059 (State or other jurisdiction (Commission (IRS Empl |
|
| July 17, 2014 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 10, 2014 Bio-Reference Laboratories, Inc. (Exact name of registrant as specified in its charter) New Jersey 0-15266 22-2405059 (State or other jurisdiction (Commission (IRS Employ |
|
| June 6, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| June 5, 2014 |
EX-99.1 2 a14-148721ex99d1.htm EX-99.1 Exhibit 99.1 FOR: BIOREFERENCE LABORATORIES, INC. CONTACT: Tara Mackay Investor Relations Coordinator (201) 791-2600 (201) 791-1941 (fax) [email protected] BIOREFERENCE LABORATORIES, INC. REPORTS RECORD QUARTERLY REVENUES AND PATIENT VOLUMES FOR SECOND QUARTER FY2014 - - - Quarterly revenues and patient volumes both increased by over 14%, cash flow ret |
|
| June 5, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 5, 2014 Bio-Reference Laboratories, Inc. (Exact name of registrant as specified in its charter) New Jersey 0-15266 22-2405059 (State or other jurisdiction (Commission (IRS Employe |
|
| June 4, 2014 |
BIO-REFERENCE LABORATORIES, INC. AMENDED AND RESTATED BY-LAWS ARTICLE I EX-3.2 2 a14-148151ex3d2.htm EX-3.2 Exhibit 3.2 BIO-REFERENCE LABORATORIES, INC. AMENDED AND RESTATED BY-LAWS ARTICLE I OFFICES Section 1. Principal Business Office. The principal business office of the corporation shall be in the Borough of Elmwood Park, State of New Jersey. Section 2. Other Offices. The corporation may also have offices at such other places both within and without the State of N |
|
| June 4, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 3, 2014 Bio-Reference Laboratories, Inc. (Exact name of registrant as specified in its charter) New Jersey 0-15266 22-2405059 (State or other jurisdiction (Commission (IRS Employe |
|
| May 28, 2014 |
DEF 14A 1 c77616def14a.htm SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant S Filed by a Party other than the Registrant £ Check the appropriate box: £ Preliminary Proxy Statement £ Soliciting Material Under Rule14a-12 £ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) S |
|
| March 10, 2014 |
TWELFTH AMENDED AND RESTATED SECURED REVOLVING NOTE (PNC Bank, National Association) EXHIBIT 10.1.2 TWELFTH AMENDED AND RESTATED SECURED REVOLVING NOTE (PNC Bank, National Association) $70,000,000.00 February 3, 2014 FOR VALUE RECEIVED, BIO-REFERENCE LABORATORIES, INC., a New Jersey corporation with an address at 481 Edward H. Ross Drive, Elmwood Park, New Jersey 07497 and its Subsidiary or Subsidiaries party hereto (collectively, jointly and severally the ?Borrowers?), promise to |
|
| March 10, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| March 10, 2014 |
EX-10.1.1 2 a14-60281ex10d1d1.htm EX-10.1.1 Exhibit 10.1.1 Thirteenth Amendment to Loan Documents THIS THIRTEENTH AMENDMENT TO LOAN DOCUMENTS (this “Amendment”) is made as of February 3, 2014, and is by and among Bio-Reference Laboratories, Inc. (“BRLI”), and GeneDX, Inc. (formerly known as BRLI No. 2 Acquisition Corp.), which conducts business as GeneDx (referred to herein from time to time as “G |
|
| March 4, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a14-731518k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 4, 2014 Bio-Reference Laboratories, Inc. (Exact name of registrant as specified in its charter) New Jersey 0-15266 22-2405059 (State or other jurisdicti |
|
| March 4, 2014 |
EX-99.1 2 a14-73151ex99d1.htm EX-99.1 Exhibit 99.1 FOR: BIO-REFERENCE LABORATORIES, INC. CONTACT: Tara Mackay, Investor Relations (201) 791-2600 (201) 791-1941 (fax) [email protected] BIO-REFERENCE LABORATORIES, INC. REPORTS REVENUE GROWTH DESPITE REIMBURSEMENT PRESSURE AND IMPACTFUL WEATHER - - - Q1FY14 results continue to show the effects of reimbursement pressures ELMWOOD PARK, NJ (March |
|
| February 13, 2014 |
BRLI / Bio-Reference Labs / MANULIFE FINANCIAL CORP - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Bio-Reference Laboratories, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09057G602 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche |
|
| February 11, 2014 |
BRLI / Bio-Reference Labs / VANGUARD GROUP INC Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1 )* Name of issuer: Bio-Reference Labs Inc Title of Class of Securities: Common Stock CUSIP Number: 09057G602 Date of Event Which Requires Filing of this Statement: December 31, 2013 Check the appropriate box to designate the rule pursuant to which this Schedule is file |
|
| January 13, 2014 |
EXHIBIT 21 The following are the Company?s wholly-owned subsidiaries: Jurisdiction of Incorporation Name under which it Conducts of Conducted Business CareEvolve. |
|
| January 13, 2014 |
2014 Senior Management Incentive Bonus Plan EX-10.5 2 a13-133101ex10d5.htm EX-10.5 EXHIBIT 10.5 2014 Senior Management Incentive Bonus Plan Participants: Marc D. Grodman, MD, CEO Wendy Chung, CSO Howard Dubinett, COO Charles T. Todd, Sr. VP Marketing & Sales Amar Karnath, VP Marketing Gary Reeves, VP, Women’s Health Scott Montgomery, VP, Clinical Don Fowler, VP, Oncology Warren Erdmann, SVP Operations Nick Cetani, VP Laboratory Director Ron |
|
| January 13, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [Mark One] x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2013 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-15266 |
|
| December 19, 2013 |
Exhibit 99.2 I am well aware of the reimbursement environment, after all, I believe we focused attention on it in our announcement three weeks ago. But, I cannot start this call without calling attention to the remarkable achievements and contributions made by the people of BioReference this year, which marks our 20th year of 20% Compound Annual Growth Rate in Revenue. Our leadership and innovatio |
|
| December 19, 2013 |
Exhibit 99.1 FOR: BIO-REFERENCE LABORATORIES, INC. CONTACT: Tara Mackay Investor Relations Coordinator (201) 791-2600 (201) 791-1941 (fax) [email protected] BIOREFERENCE LABORATORIES, INC. ANNOUNCES RECORD QUARTERLY REVENUES AND RECORD ANNUAL REVENUES AND EARNINGS DESPITE SIGNIFICANT 4TH QUARTER HEADWINDS - - - The Company displayed strong growth but faced significant reimbursement pressure |
|
| December 19, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 19, 2013 Bio-Reference Laboratories, Inc. (Exact name of registrant as specified in its charter) New Jersey 0-15266 22-2405059 (State or other jurisdiction (Commission (IRS Em |
|
| December 10, 2013 |
BRLI / Bio-Reference Labs / PRUDENTIAL FINANCIAL INC Passive Investment 13G HTML File DOCUMENT TYPE SC 13G/A TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 27, 2013 |
EX-99.1 2 a13-252381ex99d1.htm EX-99.1 Exhibit 99.1 FOR: BIOREFERENCE LABORATORIES, INC. CONTACT: Tara Mackay Investor Relations Coordinator (201) 791-2600 (201) 791-1941 (fax) [email protected] FOR IMMEDIATAE RELEASE BIOREFERENCE LABORATORIES, INC. PROVIDES GUIDANCE FOR FY13 AND Q4FY13 ANTICIPATED RESULTS Company identifies multiple factors adversely affecting results ELMWOOD PARK, NJ (Nov |
|
| November 27, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a13-2523818k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 27, 2013 Bio-Reference Laboratories, Inc. (Exact name of registrant as specified in its charter) New Jersey 0-15266 22-2405059 (State or other juris |
|
| September 6, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents [ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| August 29, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a13-1648828k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 29, 2013 Bio-Reference Laboratories, Inc. (Exact name of registrant as specified in its charter) New Jersey 0-15266 22-2405059 (State or other jurisdi |
|
| August 29, 2013 |
EX-99.1 2 a13-164882ex99d1.htm EX-99.1 Exhibit 99.1 FOR: BIOREFERENCE LABORATORIES, INC. CONTACT: Tara Mackay Investor Relations Coordinator (201) 791-2600 (201) 791-1941 (fax) [email protected] BIOREFERENCE LABORATORIES, INC. REPORTS SUSTAINED GROWTH ON STRONG QUARTERLY RESULTS - - - Company maintains growth trajectory through Q3FY13 ELMWOOD PARK, NJ (August 29, 2013) BioReference Laborato |
|
| July 11, 2013 |
Submission of Matters to a Vote of Security Holders - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 11, 2013 Bio-Reference Laboratories, Inc. (Exact name of registrant as specified in its charter) New Jersey 0-15266 22-2405059 (State or other jurisdiction (Commission (IRS Employ |
|
| June 7, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| June 6, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 6, 2013 Bio-Reference Laboratories, Inc. (Exact name of registrant as specified in its charter) New Jersey 0-15266 22-2405059 (State or other jurisdiction (Commission (IRS Emplo |
|
| June 6, 2013 |
Exhibit 99.1 FOR: BIOREFERENCE LABORATORIES, INC. CONTACT: Tara Mackay Investor Relations Coordinator (201) 791-2600 (201) 791-1941 (fax) [email protected] FOR IMMEDIATE RELEASE BIOREFERENCE LABORATORIES, INC. REPORTS RECORD QUARTERLY RESULTS BASED ON SUSTAINED GROWTH - - - Quarterly revenues and earnings highest in corporate history ELMWOOD PARK, NJ (June 6, 2013) BioReference Laboratories |
|
| June 6, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 6, 2013 Bio-Reference Laboratories, Inc. (Exact name of registrant as specified in its charter) New Jersey 0-15266 22-2405059 (State or other jurisdiction (Commission (IRS Employe |
|
| June 6, 2013 |
EX-99.1 2 v347162ex99-1.htm EXHIBIT 99.1 FOR: BIOREFERENCE LABORATORIES, INC. CONTACT: Tara Mackay Investor Relations Coordinator (201) 791-2600 (201) 791-1941 (fax) [email protected] FOR IMMEDIATE RELEASE UPDATE - BIOREFERENCE LABORATORIES, INC. REPORTS RECORD QUARTERLY RESULTS BASED ON SUSTAINED GROWTH - - - Quarterly revenues highest in corporate history ELMWOOD PARK, NJ (June 6, 2013) B |
|
| May 28, 2013 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| May 14, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 14, 2013 Bio-Reference Laboratories, Inc. (Exact name of registrant as specified in its charter) New Jersey 0-15266 22-2405059 (State or other jurisdiction (Commission (IRS Employe |
|
| March 11, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| February 28, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 28, 2013 Bio-Reference Laboratories, Inc. (Exact name of registrant as specified in its charter) New Jersey 0-15266 22-2405059 (State or other jurisdiction (Commission (IRS Em |
|
| February 28, 2013 |
Exhibit 99.1 FOR: BIO-REFERENCE LABORATORIES, INC. CONTACT: Tara Mackay, Investor Relations (201) 791-2600 (201) 791-1941 (fax) [email protected] BIO-REFERENCE LABORATORIES, INC. ANNOUNCES STRONG GROWTH RESULTING IN RECORD FIRST QUARTER REVENUE AND EARNINGS - - - Q1FY13 results reported in accordance with Update 954 reclassifications ELMWOOD PARK, NJ (February 28, 2013) Bio-Reference Labora |
|
| February 25, 2013 |
EX-99.1 2 a13-59891ex99d1.htm EX-99.1 Exhibit 99.1 FOR: BIO-REFERENCE LABORATORIES, INC. CONTACT: Tara Mackay Investor Relations Coordinator (201) 791-2600 (201) 791-1941 (fax) [email protected] BIO-REFERENCE LABORATORIES, INC. ANNOUNCES EARNINGS WILL BE REPORTED ON FEBRUARY 28, 2013, WILL REFLECT CHANGE IN PRESENTATION OF REVENUES AND BAD DEBT TO COMPLY WITH ACCOUNTING STANDARDS UPDATE TOP |
|
| February 25, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 25, 2013 Bio-Reference Laboratories, Inc. (Exact name of registrant as specified in its charter) New Jersey 0-15266 22-2405059 (State or other jurisdiction (Commission (IRS Em |
|
| February 13, 2013 |
BRLI / Bio-Reference Labs / VANGUARD GROUP INC Passive Investment bioreferencelabsinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 0 )* Name of issuer: Bio-Reference Labs Inc Title of Class of Securities: Common Stock CUSIP Number: 09057G602 Date of Event Which Requires Filing of this Statement: December 31, 2012 Check the appropria |
|
| February 13, 2013 |
BRLI / Bio-Reference Labs / MANULIFE FINANCIAL CORP - SC 13G Passive Investment SC 13G 1 d30207.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Bio-Reference Laboratories, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09057G602 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| February 11, 2013 |
BRLI / Bio-Reference Labs / PRUDENTIAL FINANCIAL INC Passive Investment DOCUMENT TYPE SC 13G/A TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment # 3 Name of Issuer: BIO REFERENCE LABORATORIES INC Title of Class of Securities: Common Stock CUSIP Number: 09057G602 1) NAME AND I.R.S. IDENTIFICATION NO. OF REPORTING PERSON Prudential Financial, Inc. 22-3703799 2.) MEMBER OF A GROUP: (a) N/A (b) |
|
| February 8, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Bio-Reference Laboratories, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 09057G602 (CUSIP Number) February 08, 2013 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the r |
|
| January 14, 2013 |
EXHIBIT 21 The following are the Company?s wholly-owned subsidiaries: Name under which it Conducts or Jurisdiction of Incorporation Conducted Business CareEvolve. |
|
| January 14, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K 10-K 1 a12-27695110k.htm 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [Mark One] x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2012 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file nu |
|
| January 14, 2013 |
2013 Senior Management Incentive Bonus Plan Exhibit 10.5.3 2013 Senior Management Incentive Bonus Plan Participants: Marc D. Grodman, MD, CEO Howard Dubinett, COO Charles T. Todd, Sr. VP Marketing & Sales Amar Kamath, VP Marketing Gary Reeves, VP, Women?s Health Warren Erdmann, SVP Operations Nick Cetani, VP Laboratory Director Ron Rayot, VP Chris Smith, VP Sam Singer, CFO Sally Howlett, VP Billing Nick Papazicos, SVP Financial Operations J |
|
| January 4, 2013 |
Exhibit 1.1 EXECUTION COPY STOCK PURCHASE AGREEMENT among FLORIDA CLINICAL LABORATORY, INC. CRAIG K. DELIGDISH, M.D. GREGG ANDREW SARGENT and BIO-REFERENCE LABORATORIES, INC. Dated as of December 31, 2012 TABLE OF CONTENTS Page 1. PURCHASE AND SALE OF STOCK 1 1.1 Transfer of Shares 1 1.2 Resignation of Officers and Directors 1 1.3 Further Assurances 1 1.4 Professional Liability Insurance 2 2. PREL |
|
| January 4, 2013 |
Entry into a Material Definitive Agreement - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act OF 1934 Date of report (date of earliest event reported): December 31, 2012 BIO-REFERENCE LABORATORIES, INC. |
|
| December 27, 2012 |
EX-1.1 2 a12-301871ex1d1.htm EX-1.1 Exhibit 1.1 STOCK PURCHASE AGREEMENT among MERIDIAN CLINICAL LABORATORY CORPORATION MARIA ACOSTA CARLOS MIGUEL ACOSTA and BIO-REFERENCE LABORATORIES, INC. Dated as of December 21, 2012 TABLE OF CONTENTS Page 1. PURCHASE AND SALE OF STOCK 5 1.1 Transfer of Shares 5 1.2 Resignation of Officers and Directors; Termination of Management Agreement 5 1.3 Further Assura |
|
| December 27, 2012 |
Entry into a Material Definitive Agreement - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act OF 1934 Date of report (date of earliest event reported): December 21, 2012 BIO-REFERENCE LABORATORIES, INC. |
|
| December 6, 2012 |
Exhibit 99.1 FOR: BIO-REFERENCE LABORATORIES, INC. CONTACT: Delores Bowman Acting Investor Relations Coordinator (201) 791-2600 (201) 791-1941 (fax) [email protected] BIO-REFERENCE LABORATORIES, INC. ANNOUNCES RECORD REVENUES AND EARNINGS FOR FOURTH QUARTER AND FOR FULL FISCAL YEAR DESPITE EFFECTS OF HURRICANE SANDY Despite the effects of Hurricane Sandy, the Company had a record fourth qua |
|
| December 6, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 6, 2012 Bio-Reference Laboratories, Inc. (Exact name of registrant as specified in its charter) New Jersey 0-15266 22-2405059 (State or other jurisdiction (Commission (IRS Emp |
|
| September 6, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| August 30, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 30, 2012 Bio-Reference Laboratories, Inc. (Exact name of registrant as specified in its charter) New Jersey 0-15266 22-2405059 (State or other jurisdiction (Commission (IRS Empl |
|
| August 30, 2012 |
Exhibit 99.1 FOR: BIO-REFERENCE LABORATORIES, INC. CONTACT: Delores Bowman Acting Investor Relations Coordinator (201) 791-2600 (201) 791-1941 (fax) [email protected] Bio-Reference Laboratories, Inc. reports best quarterly revenues and earnings in corporate history with 25% increase in earnings per share - - - The Company continues to show solid results for all financial metrics including c |
|
| August 7, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 12, 2012 Bio-Reference Laboratories, Inc. (Exact name of registrant as specified in its charter) New Jersey 0-15266 22-2405059 (State or other jurisdiction (Commission (IRS Employ |
|
| June 15, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 14, 2012 Bio-Reference Laboratories, Inc. (Exact name of registrant as specified in its charter) New Jersey 0-15266 22-2405059 (State or other jurisdiction (Commission (IRS Employ |
|
| June 15, 2012 |
EX-99.2 3 a12-148361ex99d2.htm EX-99.2 Exhibit 99.2 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) dated as of February 1, 2012 (the “Effective Date”), between Bio-Reference Laboratories, Inc., a New Jersey corporation with its principal place of business at 481 Edward H. Ross Drive, Elmwood Park, New Jersey 07407 (the “Company”) and Sam Singer (the “Employee”). W I T N E S S E |
|
| June 15, 2012 |
EX-99.1 2 a12-148361ex99d1.htm EX-99.1 Exhibit 99.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) dated as of February 1, 2012 (the “Effective Date”), between Bio-Reference Laboratories, Inc., a New Jersey corporation with its principal place of business at 481 Edward H. Ross Drive, Elmwood Park, New Jersey 07407 (the “Company”) and Howard Dubinett (the “Employee”). W I T N E S |
|
| June 8, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| June 7, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 7, 2012 Bio-Reference Laboratories, Inc. (Exact name of registrant as specified in its charter) New Jersey 0-15266 22-2405059 (State or other jurisdiction (Commission (IRS Employe |
|
| June 7, 2012 |
EX-99.1 2 a12-142541ex99d1.htm EX-99.1 Exhibit 99.1 FOR: BIO-REFERENCE LABORATORIES, INC. CONTACT: Delores Bowman Acting Investor Relations Coordinator (201) 791-2600 (201) 791-1941 (fax) [email protected] BIO-REFERENCE LABORATORIES, INC. REPORTS STRONG QUARTERLY RESULTS - - - Quarterly revenues highest in corporate history ELMWOOD PARK, NJ (June 7, 2012) (Numbers in thousands except per sh |
|
| June 6, 2012 |
SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| May 1, 2012 |
Entry into a Material Definitive Agreement 8-K 1 a12-1090018k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act OF 1934 Date of report (date of earliest event reported): April 27, 2012 BIO-REFERENCE LABORATORIES, INC. (Exact Name of Registrant as Specified in Its Charter) New Jersey (State or Other Jurisdiction of Incorporatio |
|
| May 1, 2012 |
INCELLDX, INC. SERIES A-1 PREFERRED STOCK PURCHASE AGREEMENT EXHIBIT 1.2 INCELLDX, INC. SERIES A-1 PREFERRED STOCK PURCHASE AGREEMENT THIS SERIES A-1 PREFERRED STOCK PURCHASE AGREEMENT (this “Agreement”) is made as of April 27, 2012 by and among InCellDx, Inc., a Delaware corporation (the “Company”) and each of the investors, severally and not jointly, listed on the Schedule of Purchasers attached hereto as Exhibit A (each of which is herein referred to as |
|
| May 1, 2012 |
EXHIBIT 1.1 FOR: BIO-REFERENCE LABORATORIES, INC. CONTACT: Tara Mackay, Investor Relations (201) 791-2600 (201) 791-1941 (fax) [email protected] For Immediate Release BRLI Announces InCellDx Investment and Launch of GenCerv test through its GenPath Women’s Health Laboratory GenCerv screening expected to reduce unnecessary and risky colposcopy and biopsy procedures Elmwood Park, NJ, April 30 |
|
| March 22, 2012 |
BIO-REFERENCE LABORATORIES, INC. AMENDMENT NO. 1 EMPLOYMENT AGREEMENT WITH MARC D. GRODMAN, M.D. Exhibit 99.1 BIO-REFERENCE LABORATORIES, INC. AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT WITH MARC D. GRODMAN, M.D. AMENDMENT NO. 1 dated as of March 7, 2012 to an Employment Agreement (the “Employment Agreement”) dated effective December 31, 2010 between Bio-Reference Laboratories, Inc., a New Jersey corporation (the “Company”) and Marc D. Grodman, M.D., its Chief Executive Officer (the “Employee”). |
|
| March 22, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 19, 2012 Bio-Reference Laboratories, Inc. (Exact name of registrant as specified in its charter) New Jersey 0-15266 22-2405059 (State or other jurisdiction (Commission (IRS Emplo |
|
| March 8, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| March 1, 2012 |
Exhibit 99.1 FOR: BIO-REFERENCE LABORATORIES, INC. CONTACT: Tara Mackay, Investor Relations (201) 791-2600 (201) 791-1941 (fax) [email protected] FOR IMMEDIATE RELEASE BIO-REFERENCE LABORATORIES, INC. ANNOUNCES RECORD FIRST QUARTER REVENUE, EARNINGS AND CASH FLOW FROM OPERATIONS - - - Q1FY12 financials demonstrate sustained success ELMWOOD PARK, NJ (March 1, 2012) (except for per share data |
|
| March 1, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 1, 2012 Bio-Reference Laboratories, Inc. (Exact name of registrant as specified in its charter) New Jersey 0-15266 22-2405059 (State or other jurisdiction (Commission (IRS Employ |
|
| February 14, 2012 |
BRLI / Bio-Reference Labs / PRUDENTIAL FINANCIAL INC Passive Investment 13G HTML File DOCUMENT TYPE SC 13G/A TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 9, 2012 |
SC 13G 1 brlt20812.htm PALISADE CAPITAL MANAGEMENT LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Bio-Reference Laboratories, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 09057G602 (CUSIP Number) December 31, 2011 (Date of Event which Requires Filing of this S |
|
| February 8, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 8, 2012 Bio-Reference Laboratories, Inc. (Exact name of registrant as specified in its charter) New Jersey 0-15266 22-2405059 (State or other jurisdiction (Commission (IRS Emp |
|
| February 8, 2012 |
BIO-REFERENCE LABORATORIES, INC. Exhibit 99.1 BIO-REFERENCE LABORATORIES, INC. Investor Contact: Bio-Reference Laboratories, Inc. Tara Mackay, Investor Relations 201-791-2600 201-791-1941 (fax) [email protected] For Release: February 8, 2012 BIOREFERENCE ANNOUNCES 2012 ANNUAL MEETING DATE (Elmwood Park, New Jersey February 8, 2012) — Bio-Reference Laboratories, Inc. (“BioReference”) (NASDAQ: BRLI) announced today that it w |
|
| January 13, 2012 |
Exhibit 3.1.3 FILED MAR 27 1998 LONNA R. HOCKS Secretary of State CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF BIO-REFERENCE LABORATORIES, INC. To: The Secretary of State State of New Jersey Pursuant to the provisions of Section 14A: 7-2(2), Corporations, General, of the New Jersey Statutes, the undersigned corporation executes this certificate of amendment to its certificate of |
|
| January 13, 2012 |
Exhibit 3.1.1 FILED AUG 23 1993 DANIEL J. DALTON Secretary of State CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF Incorporation OF BIO-REFERENCE LABORATORIES, INC. To: The Secretary of State State of New Jersey Pursuant to the provisions of Section 14A:Z-15.1, Corporations, General, of the New Jersey Statutes, the undersigned corporation executes this certificate of amendment to its certificate o |
|
| January 13, 2012 |
EX-3.1.5 7 a11-315041ex3d1d5.htm EX-3.1.5 Exhibit 3.1.5 FILED SEP 26 2003 State Treasurer CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF BIO-REFERENCE LABORATORIES, INC. To: The Secretary of State State of New Jersey Pursuant to the provisions of Section 14A: 9-4, Corporations, General, of the New Jersey Statutes, the undersigned corporation executes this certificate of amendment |
|
| January 13, 2012 |
BIO-REFERENCE LABORATORIES, INC. AMENDED AND RESTATED BY-LAWS ARTICLE I Exhibit No. 3.2.2 BIO-REFERENCE LABORATORIES, INC. AMENDED AND RESTATED BY-LAWS ARTICLE I OFFICES Section 1. Principal Office. The principal office of the corporation shall be in the Borough of Elmwood Park, State of New Jersey. Section 2. Other Offices. The corporation may also have offices at such other places both within and without the State of New Jersey as the board of directors (sometimes h |
|
| January 13, 2012 |
BIO-REFERENCE LABORATORIES AMENDMENT NO. 4 EMPLOYMENT AGREEMENT WITH SAM SINGER EX-10.3.4 9 a11-315041ex10d3d4.htm EX-10.3.4 Exhibit 10.3.4 BIO-REFERENCE LABORATORIES AMENDMENT NO. 4 TO EMPLOYMENT AGREEMENT WITH SAM SINGER AMENDMENT NO. 4 dated March 4, 2008, to an AGREEMENT OF EMPLOYMENT dated as of May 1, 1997 between Bio-Reference Laboratories, Inc., a New Jersey corporation (the “Company”) and Sam Singer, its Senior Vice President and Chief Financial Officer (the “Employe |
|
| January 13, 2012 |
EXHIBIT 21 The following are the Company?s wholly-owned subsidiaries: Name under which it Conducts or Jurisdiction of Incorporation Conducted Business CareEvolve. |
|
| January 13, 2012 |
2012 Senior Management Incentive Bonus Plan EX-10.5.2 14 a11-315041ex10d5d2.htm EX-10.5.2 Exhibit 10.5.2 2012 Senior Management Incentive Bonus Plan Participants: Marc D. Grodman, MD, CEO Howard Dubinett, COO Charles T. Todd, Sr. VP Marketing & Sales Amar Kamath, VP Marketing Gary Reeves, VP, Women’s Health Warren Erdmann, SVP Operations Nick Cetani, VP Laboratory Director Ron Rayot, VP Chris Smith, VP Sam Singer, CFO Sally Howlett, VP Bill |
|
| January 13, 2012 |
BIO-REFERENCE LABORATORIES AMENDMENT NO. 6 EMPLOYMENT AGREEMENT WITH SAM SINGER Exhibit 10.3.6 BIO-REFERENCE LABORATORIES AMENDMENT NO. 6 TO EMPLOYMENT AGREEMENT WITH SAM SINGER AMENDMENT NO. 6 dated as of October , 2009 to an AGREEMENT OF EMPLOYMENT dated as of May 1, 1997 between Bio-Reference Laboratories, Inc., a New Jersey corporation (the “Company”) and Sam Singer, its Senior Vice President and Chief Financial Officer (the “Employee”); as amended on November 1, 2002 (Am |
|
| January 13, 2012 |
EX-10.6.4 15 a11-315041ex10d6d4.htm EX-10.6.4 Exhibit 10.6.4 Seventh Amendment to Loan Documents THIS SEVENTH AMENDMENT TO LOAN DOCUMENTS (this “Amendment”) is made as of Oct. 22, 2010, and is by and among Bio-Reference Laboratories, Inc. (“BRLI”), and BRLI No. 2 Acquisition Corp., which conducts business as GENEDX, Inc. (referred to herein from time to time as a “Subsidiary Party”) (BRLI and the |
|
| January 13, 2012 |
BIO-REFERENCE LABORATORIES AMENDMENT NO. 7 EMPLOYMENT AGREEMENT WITH SAM SINGER EX-10.3.7 12 a11-315041ex10d3d7.htm EX-10.3.7 Exhibit 10.3.7 BIO-REFERENCE LABORATORIES AMENDMENT NO. 7 TO EMPLOYMENT AGREEMENT WITH SAM SINGER AMENDMENT NO. 7 dated as of November 1, 2010 to an AGREEMENT OF EMPLOYMENT dated as of May 1, 1997 between Bio-Reference Laboratories, Inc., a New Jersey corporation (the “Company”) and Sam Singer, its Senior Vice President and Chief Financial Officer (the |
|
| January 13, 2012 |
Exhibit 10.5.1 2011 Senior Management Incentive Bonus Plan Participants: Marc D. Grodman, MD, CEO Howard Dubinett, COO Charles T. Todd, Sr. VP Marketing & Sales Amar Kamath, VP Marketing Gary Reeves, VP, Women?s Health Warren Erdmann, SVP Operations Nick Cetani, VP Laboratory Director Ron Rayot, VP Chris Smith, VP Sam Singer, SVP and CFO Sally Howlett, VP Billing Nick Papazicos, SVP Financial Oper |
|
| January 13, 2012 |
BIO-REFERENCE LABORATORIES AMENDMENT NO. 5 EMPLOYMENT AGREEMENT WITH SAM SINGER EX-10.3.5 10 a11-315041ex10d3d5.htm EX-10.3.5 Exhibit 10.3.5 BIO-REFERENCE LABORATORIES AMENDMENT NO. 5 TO EMPLOYMENT AGREEMENT WITH SAM SINGER Bio-Reference Laboratories, Inc. (the “Company”) and Sam Singer (the “Employee”) hereby mutually agree that Section 8(d) as set forth in Amendment No. 4 dated March 4, 2008 to the Employment Agreement between the Company and the Employee is hereby deleted |
|
| January 13, 2012 |
Exhibit 3.1.4 FILED MAR 31 1998 LONNA R. HOOKS Secretary of State CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION of BIO-REFERENCE LABORATORIES, INC. To: The Secretary of State State of New Jersey Pursuant to the provisions of Section 14A:7-2(2), Corporations, General, of the New Jersey statutes, the undersigned corporation executes this certificate of amendment to its certificate of |
|
| January 13, 2012 |
Exhibit 3.1 FILED NOV 15 1989 JANE BURGIO Secretary of State AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MED-MOBILE, INC. The undersigned corporation, in order to amend and restate its Certificate of Incorporation, hereby certifies as follows: FIRST: The name of the corporation is BIO-REFERENCE LABORATORIES, INC. SECOND: The Corporation was originally incorporated in New Jersey on Decembe |
|
| January 13, 2012 |
Exhibit 10.6.5 Execution Version Eighth Amendment to Loan Documents THIS EIGHTH AMENDMENT TO LOAN DOCUMENTS (this ?Amendment?) is made as of October 31, 2011, and is by and among Bio-Reference Laboratories, Inc. (?BRLI?), and BRLI No. 2 Acquisition Corp., which conducts business as GeneDx (referred to herein from time to time as ?GeneDx? and a ?Subsidiary Party?) (BRLI and the Subsidiary Party her |
|
| January 13, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K 10-K 1 a11-31504110k.htm 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [Mark One] x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2011 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file nu |
|
| January 13, 2012 |
Exhibit 3.1.2 FILED AUG 28 1993 DANIEL J. DALTON Secretary of State CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF BIO-REFERENCE LABORATORIES, INC. To: The Secretary of State State of New Jersey Pursuant to the provisions of Section 14A:7-2(2), Corporations, General; of the New Jersey Statutes, the undersigned corporation executes this certificate of amendment to its certificate o |
|
| December 14, 2011 |
Exhibit 99.2 |
|
| December 14, 2011 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 8, 2011 Bio-Reference Laboratories, Inc. (Exact name of registrant as specified in its charter) New Jersey 0-15266 22-2405059 (State or other jurisdiction (Commission (IRS Emp |
|
| December 14, 2011 |
Exhibit 99.1 FOR: BIO-REFERENCE LABORATORIES, INC. CONTACT: Tara Mackay, Investor Relations (201) 791-2600 (201) 791-1941 (fax) [email protected] FOR IMMEDIATE RELEASE BIO-REFERENCE LABORATORIES, INC. ANNOUNCES RECORD REVENUES, EARNINGS AND CASH FLOW FOR FOURTH QUARTER AND FULL FISCAL YEAR - - - New diagnostic initiatives expected to be introduced by the end of the first quarter 2012 ELMWOO |
|
| November 10, 2011 |
By signing below, Prudential Financial, Inc. certifies that, to the best of its DOCUMENT TYPE SC 13G/A TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment # 1 Name of Issuer: BIO REFERENCE LABORATORIES INC Title of Class of Securities: Common Stock CUSIP Number: 09057G602 1) NAME AND I.R.S. IDENTIFICATION NO. OF REPORTING PERSON Prudential Financial, Inc. 22-3703799 2.) MEMBER OF A GROUP: (a) N/A (b) |
|
| November 4, 2011 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 2, 2011 Bio-Reference Laboratories, Inc. (Exact name of registrant as specified in its charter) New Jersey 0-15266 22-2405059 (State or other jurisdiction (Commission (IRS Emp |
|
| September 8, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 8, 2011 Bio-Reference Laboratories, Inc. (Exact name of registrant as specified in its charter) New Jersey 0-15266 22-2405059 (State or other jurisdiction (Commission (IRS Em |
|
| September 6, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| August 1, 2011 |
SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| July 14, 2011 |
Table of Contents SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A AMENDMENT TO ANNUAL REPORT ON FORM 10-K FILED PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2010 BIO-REFERENCE LABORATORIES, INC. [Exact name of Registrant as specified in its charter] Commission file number 0-15266 AMENDMENT NO. 1 Table of Contents |
|
| July 7, 2011 |
July 07, 2011 John Reynolds Esq. Assistant Director, Division of Corporate Finance U.S. Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 www.sec.gov Re: BioReference Laboratories, Inc. Form 10-K for the Fiscal Year ended October 31, 2010 Filed January 14, 2011 File No. 000-15266 Form 10-K for the Fiscal Year Ended October 31, 2010 Management?s Discussion and Analysis, pag |
|
| June 10, 2011 |
June 10, 2011 John Reynolds Esq. Assistant Director, Division of Corporate Finance U.S. Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 www.sec.gov Re: BioReference Laboratories, Inc. Form 10-K for the Fiscal Year ended October 31, 2010 Filed January 14, 2011 File No. 000-15266 Form 10-K for the Fiscal Year Ended October 31, 2010 1. Please confirm that you will incorpora |
|
| June 7, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| April 21, 2011 |
April 20, 2011 John Reynolds Esq. Assistant Director, Division of Corporate Finance U.S. Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 www.sec.gov Re: Bio-Reference Laboratories, Inc. (BRLI) Form 10-K for Fiscal Year Ended October 31, 2010 Dear Mr. Reynolds, We have reviewed the staff?s comment letter of March 28, 2011 in which the substantive paragraphs of the staff?s |
|
| April 8, 2011 |
April 8, 2011 John Reynolds, Esq. Assistant Director Securities and Exchange Commission 450 Fifth Street N.W. Washington, D.C. 20549 Re: Bio-Reference Laboratories, Inc. Annual Report on form 10-K for the year ended Oct., 31, 2010 Dear Mr. Reynolds, In accordance with our counsel’s telephone conversation today with Edwin Kim, Esq., Bio-Reference Laboratories, Inc. hereby respectfully requests a te |
|
| March 11, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| February 8, 2011 |
By signing below, Prudential Financial, Inc. certifies that, to the best of its DOCUMENT TYPE SC 13G TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Name of Issuer: BIO REFERENCE LABORATORIES INC Title of Class of Securities: Common Stock CUSIP Number: 09057G602 1) NAME AND I.R.S. IDENTIFICATION NO. OF REPORTING PERSON Prudential Financial, Inc. 22-3703799 2.) MEMBER OF A GROUP: (a) N/A (b) N/A 3) SEC USE O |
|
| January 14, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [Mark One] x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2010 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 159d) OF THE SEUCIRITES EXHANGE ACT OF 1934 For the transition period from to Commission file number 0-15266 BIO-REFERENCE LABOR |
|
| January 14, 2011 |
EX-10.9.2 2 a11-35251ex10d9d2.htm EX-10.9.2 Exhibit 10.9.2 2010 Senior Management Incentive Bonus Plan Participants: Marc D. Grodman, MD, CEO Howard Dubinett, COO Charles T. Todd, Sr. VP Marketing & Sales Amar Kamath, VP Marketing Warren Erdmann, VP Operations Nick Cetani, VP Laboratory Director Ron Rayot, VP Chris Smith, VP Sam Singer, CFO Sally Howlett, VP Billing Nick Papazicos, VP Financial Op |
|
| January 5, 2011 |
EX-10.2.1 2 a11-14501ex10d2d1.htm EX-10.2.1 Exhibit: 10.2.1 EMPLOYMENT AGREEMENT This Employment Agreement dated effective the 31st day of December, 2010 between Bio-Reference Laboratories, Inc., a New Jersey corporation with its principal place of business at 481 Edward H. Ross Drive, Elmwood Park, New Jersey 07407 (the “Company”) and Marc D. Grodman M.D. residing at R.D. No. 1, P.O. Box 309, Cal |
|
| January 5, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 31, 2010 Bio-Reference Laboratories, Inc. (Exact name of registrant as specified in its charter) New Jersey 0-15266 22-2405059 (State or other jurisdiction (Commission (IRS Em |
|
| September 3, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| September 3, 2010 |
Exhibit: 22.1 Report regarding matters submitted to vote of security holders Our Annual Meeting of Stockholders was held on July 22, 2010. At the meeting, the following two individuals were elected by the following vote to serve as Class I directors, each for a term of three years and until his successor is duly elected and qualified. For Withheld Marc D. Grodman 19,626,873 1,517,181 Howard Dubine |
|
| June 4, 2010 |
CONSOLIDATED STATEMENTS OF CASH FLOWS MANAGEMENT’S DISCUSSION AND ANALYSIS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| April 8, 2010 |
EX-99.2 3 a10-77401ex99d2.htm EX-99.2 Exhibit 99.2 FOR: BIOREFERENCE LABORATORIES, INC. CONTACT: Tara Mackay, Investor Relations (201) 791-2600 (201) 791-1941 (fax) [email protected] BIOREFERENCE LABORATORIES, INC. ANNOUNCES 2 FOR 1 STOCK SPLIT - - - Company will execute stock split on April 19, 2010 ELMWOOD PARK, NJ (Wednesday, April 7, 2010)- BioReference Laboratories, Inc. (NASDAQ: BRLI) |
|
| April 8, 2010 |
NOTICE OF TWO FOR ONE COMMON STOCK SPLIT Exhibit 99.1 NOTICE OF TWO FOR ONE COMMON STOCK SPLIT NASDAQ Corporate Data Dep?t April 7, 2010 2 Corporate Drive ? 300 Shelton, CT 06484 Re: Bio-Reference Laboratories (?BRLI?) Ladies and Gentlemen, Pursuant to Securities Exchange Act Rule 10b-17, notice is hereby given that BRLI?s board of directors has approved and declared a two for one stock split of its Common Stock. Pursuant to the stock sp |
|
| April 8, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 7, 2010 Bio-Reference Laboratories, Inc. (Exact name of registrant as specified in its charter) New Jersey 0-15266 22-2405059 (State or other jurisdiction (Commission (IRS Employ |
|
| April 1, 2010 |
celadon13g123108.htm - Generated by SEC Publisher for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Celadon Group, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 150838100 (CUSIP Number) 12/31/2008 (Date of Event Which Requires Filing of this Statement) Check the appropr |
|
| April 1, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| March 5, 2010 |
10-Q 1 a10-5213110q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended January 31, 2010 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission F |
|
| January 15, 2010 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* BIO-REFERENCE LABORATORIES, INC. (Name of Issuer) Common Stock, $0.01 Par Value (Title of Class of Securities) 09057G602 (CUSIP Number) December 31, 2009 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| January 12, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [Mark One] x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2009 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 159d) OF THE SEUCIRITES EXHANGE ACT OF 1934 For the transition period from to Commission file number 0-15266 BIO-REFERENCE LABOR |
|
| January 12, 2010 |
Exhibit 10.9.1 2010 Senior Management Incentive Bonus Plan Participants: Marc D. Grodman, MD, CEO Howard Dubinett, COO Charles T. Todd, Sr. VP Marketing & Sales Amar Kamath, VP Marketing Warren Erdmann, VP Operations Nick Cetani, VP Laboratory Director Ron Rayot, VP Chris Smith, VP Sam Singer, CFO Sally Howlett, VP Billing Nick Papazicos, VP Financial Operations James Weisberger, MD, CMO Maryanne |
|
| September 8, 2009 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| June 8, 2009 |
CHIEF EXECUTIVE OFFICER CERTIFICATION Exhibit: 31A CHIEF EXECUTIVE OFFICER CERTIFICATION I, Marc D. Grodman, Chief Executive Officer of Bio-Reference Laboratories, Inc. (the “Company”) do hereby certify that: I have reviewed this quarterly report on Form 10-Q of the Company for the quarterly period ended April 30, 2009 Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to stat |
|
| June 8, 2009 |
18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit: 32B CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Sam Singer, Chief Financial Officer of Bio-Reference Laboratories, Inc. (the “Company”), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: (a) the Quarterly Report on Form 10-Q of the C |
|
| June 8, 2009 |
Exhibit 32A CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Marc D. Grodman, Chief Executive Officer of Bio-Reference Laboratories, Inc. (the “Company”), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: (a) the Quarterly Report on Form 10-Q of t |
|
| June 8, 2009 |
CHIEF FINANCIAL OFFICER CERTIFICATION Exhibit: 31B CHIEF FINANCIAL OFFICER CERTIFICATION I, Sam Singer, Chief Financial Officer of Bio-Reference Laboratories, Inc. |
|
| June 8, 2009 |
10-Q 1 a09-14961110q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended April 30, 2009 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECUTRIES EXCHANGE ACT OF 1934 For the transition period from |
|
| March 11, 2009 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| February 13, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 29, 2009 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) BIO-REFERENCE LABORATORIES, INC. - (Name of Issuer) Common Stock, $.01 par value - (Title of Class of Securities) 09057G602 - (CUSIP Number) December 31, 2008 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| January 28, 2009 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A AMENDMENT TO ANNUAL REPORT ON FORM 10-K FILED PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2007 BIO-REFERENCE LABORATORIES, INC. [Exact name of Registrant as specified in its charter] Commission file number 0-15266 AMENDMENT NO. 2 The undersigned Registrant hereby a |
|
| January 26, 2009 |
Exhibit 10.14 RESTITUTION AGREEMENT WHEREAS, Bio-Reference Laboratories, Inc. (hereinafter referred to as ?BRLI? or the ?Company?) entrusted its employee, John Littleton (hereinafter referred to as the ?Employee?), with responsibility for day-to-day management of the sales force at BRLI; and WHEREAS, BRLI has discovered and its investigation has revealed that approximately $1,600,000 in funds have |
|
| January 26, 2009 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 23, 2009 Bio-Reference Laboratories, Inc. (Exact name of registrant as specified in its charter) New Jersey 0-15266 22-2405059 (State or other jurisdiction (Commission (IRS Emp |
|
| January 14, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [Mark One] x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2008 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 159d) OF THE SEUCIRITES EXHANGE ACT OF 1934 For the transition period from to Commission file number 0-15266 BIO-REFERENCE LABOR |
|
| January 14, 2009 |
Susann Reilly, Esq. – Mail Stop 3561 January 12, 2009 Office of Beverages, Apparel and Health Care Services Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Bio-Reference Laboratories, Inc. (“BRLI”) Form 10-K(as amended) for Fiscal Year Ended October 31, 2007; 10-Q for Quarter Ended January 31, 2008 10-Q for Quarter Ended April 30, 2008 10-Q for Quarter Ended July 3 |
|
| January 14, 2009 |
2008 Senior Management Incentive Bonus Plan EX-10.9 2 a09-30661ex10d9.htm EX-10.9 Exhibit 10.9 2008 Senior Management Incentive Bonus Plan Participants: Marc D. Grodman, MD, CEO Howard Dubinett, COO Sam Singer, CFO Charles T. Todd, Sr. VP Marketing & Sales John Littleton, VP Sales Warren Erdmann, VP Operations Sally Howlett, VP Billing Nick Papazicos, VP Financial Operations Nick Cetani, VP Laboratory Director James Weisberger, MD, CMO Mary |
|
| January 14, 2009 |
Exhibit 10.13.3 TENTH AMENDED AND RESTATED SECURED REVOLVING NOTE (PNC Bank, National Association) $40,000,000.00 As of May 12, 2008 FOR VALUE RECEIVED, BIO-REFERENCE LABORATORIES, INC., a New Jersey corporation with an address at 481 Edward H. Ross Drive, Elmwood Park, New Jersey 07497 and its Subsidiary or Subsidiaries party hereto (collectively, jointly and severally the “Borrowers”), promise t |
|
| December 18, 2008 |
Susann Reilly, Esq. — Mail Stop 3561 December 17, 2008 Susann Reilly, Esq. ? Mail Stop 3561 Office of Beverages, Apparel and Health Care Services Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Bio-Reference Laboratories, Inc. (?BRLI?) Form 10-K for Fiscal Year Ended October 31, 2007 Schedule 14A for July 17, 2008 Annual Meeting of Stockholders Dear Ms. Reilly, In accordance with your telephone conver |
|
| November 24, 2008 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A AMENDMENT TO ANNUAL REPORT ON FORM 10-K FILED PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2007 BIO-REFERENCE LABORATORIES, INC. [Exact name of Registrant as specified in its charter] Commission file number 0-15266 AMENDMENT NO. 1 The undersigned Registrant hereby a |
|
| November 17, 2008 |
Contingent Purchase Price (Payable Solely in Cash) First Annual Measuring Period November 17, 2008 Susann Reilly, Esq. – Mail Stop 3561 Office of Beverages, Apparel and Health Care Services Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Bio-Reference Laboratories, Inc. (“BRLI”) Form 10-K for Fiscal Year Ended October 31, 2007 Schedule 14A for July 17, 2008 Annual Meeting of Stockholders Dear Ms. Reilly, We have reviewed the staff’s comment let |
|
| September 5, 2008 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| September 5, 2008 |
September 5, 2008 Securities and Exchange Commission Judiciary Plaza 450 Fifth Street, N. |
|
| June 6, 2008 |
CHIEF EXECUTIVE OFFICER CERTIFICATION Exhibit: 31.A CHIEF EXECUTIVE OFFICER CERTIFICATION I, Marc D. Grodman, Chief Executive Officer of Bio-Reference Laboratories, Inc. (the “Company”) do hereby certify that: I have reviewed this quarterly report on Form 10-Q of the Company for the quarterly period ended April 30, 2008 Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to sta |
|
| June 6, 2008 |
Exhibit 32.A CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Marc D. Grodman, Chief Executive Officer of Bio-Reference Laboratories, Inc. (the “Company”), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: (a) the Quarterly Report on Form 10-Q of |
|
| June 6, 2008 |
June 6, 2008 Securities and Exchange Commission Judiciary Plaza 450 Fifth Street, N. |
|
| June 6, 2008 |
CHIEF FINANCIAL OFFICER CERTIFICATION Exhibit: 31.B CHIEF FINANCIAL OFFICER CERTIFICATION I, Sam Singer, Chief Financial Officer of Bio-Reference Laboratories, Inc. (the “Company”) do hereby certify that: I have reviewed this quarterly report on Form 10-Q of the Company for the quarterly period ended April 30, 2008 Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a |
|
| June 6, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| June 6, 2008 |
18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit: 32.B CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Sam Singer, Chief Financial Officer of Bio-Reference Laboratories, Inc. (the “Company”), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: (a) the Quarterly Report on Form 10-Q of the |
|
| March 11, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| March 11, 2008 |
CHIEF FINANCIAL OFFICER CERTIFICATION Exhibit: 31B CHIEF FINANCIAL OFFICER CERTIFICATION I, Sam Singer, Chief Financial Officer of Bio-Reference Laboratories, Inc. |
|
| March 11, 2008 |
Exhibit 32A CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Marc D. Grodman, Chief Executive Officer of Bio-Reference Laboratories, Inc. (the ?Company?), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: (a) the Quarterly Report on Form 10-Q of t |
|
| March 11, 2008 |
18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit: 32B CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Sam Singer, Chief Financial Officer of Bio-Reference Laboratories, Inc. (the ?Company?), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: (a) the Quarterly Report on Form 10-Q of the C |
|
| March 11, 2008 |
CHIEF EXECUTIVE OFFICER CERTIFICATION Exhibit: 31A CHIEF EXECUTIVE OFFICER CERTIFICATION I, Marc D. Grodman, Chief Executive Officer of Bio-Reference Laboratories, Inc. (the “Company”) do hereby certify that: I have reviewed this quarterly report on Form 10-Q of the Company for the quarterly period ended January 31, 2008 Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to st |
|
| March 11, 2008 |
March 10, 2008 Securities and Exchange Commission Judiciary Plaza 450 Fifth Street, N. |
|
| February 29, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 27, 2008 Bio-Reference Laboratories, Inc. (Exact name of registrant as specified in its charter) New Jersey 0-15266 22-2405059 (State or other jurisdiction (Commission (IRS Em |
|
| February 14, 2008 |
OMB APPROVAL OMB Number: 3235-0145 Expires: February 28, 2009 Estimated average burden hours per response. |
|
| February 5, 2008 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) BIO-REFERENCE LABORATORIES, INC. - (Name of Issuer) Common Stock, $.01 par value - (Title of Class of Securities) 09057G602 - (CUSIP Number) December 31, 2007 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| February 4, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Bio-Reference Laboratories Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09057G602 (CUSIP Number) 12/31/2007 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| January 14, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2007 Commission file number 0-15266 BIO-REFERENCE LABORATORIES, INC. New Jersey 22-2405059 (State of incorporation) (I.R.S. Employer Identification No.) 481 Edward H. Ross Drive, Elmwood Park, Ne |
|
| January 14, 2008 |
2007 Senior Management Incentive Bonus Plan Exhibit 10.9 2007 Senior Management Incentive Bonus Plan Participants: Marc D. Grodman, MD, CEO Howard Dubinett, COO Sam Singer, CFO Charles T. Todd, Sr. VP Marketing & Sales John Littleton, VP Sales Warren Erdmann, VP Operations Sally Howlett, VP Billing Nick Papazicos, VP Financial Operations Nick Cetani, VP Laboratory Director James Weisberger, MD, CMO Maryanne Amato, Director, Genpath Richard |
|
| January 14, 2008 |
AMENDMENT NO. 3 EMPLOYMENT AGREEMENT EX-10.3.3 2 a08-17801ex10d3d3.htm EX-10.3.3 Exhibit 10.3.3 AMENDMENT NO. 3 TO EMPLOYMENT AGREEMENT AMENDMENT NO. 3 dated as of December 18, 2007 to an EMPLOYMENT AGREEMENT entered into as of May 1, 1997 between Bio-Reference Laboratories, Inc., a New Jersey corporation (“the Company”) and Howard Dubinett, Executive Vice President (“Employee”), previously amended as of November 1, 2002 by Amendment |
|
| January 14, 2008 |
AMENDMENT NO. 3 EMPLOYMENT AGREEMENT Exhibit 10.4.3 AMENDMENT NO. 3 TO EMPLOYMENT AGREEMENT AMENDMENT NO. 3 dated as of December 18, 2007 to an EMPLOYMENT AGREEMENT entered into as of May 1, 1997 between Bio-Reference Laboratories, Inc., a New Jersey corporation (?the Company?) and Sam Singer, Senior Vice President (?Employee?), previously amended as of November 1, 2002 by Amendment No.1 and as of January 7, 2004 by Amendment No.2 (t |
|
| January 14, 2008 |
Exhibit 10.13.2 Fifth Amendment to Loan Documents THIS FIFTH AMENDMENT TO LOAN DOCUMENTS (this ?Amendment?) is made as of October 31, 2007, and is by and among Bio-Reference Laboratories, Inc. (?BRLI?), and BRLI No. 2 Acquisition Corp., which conduct business as Gene DX, Inc. (?BRLI-DX? and a ?Subsidiary Party?) (BRLI and the Subsidiary Party herein each a ?Borrower? and, collectively, ?Borrowers? |
|
| November 20, 2007 |
November 20, 2007 Tia Jenkins ? Mail Stop 3561 Senior Assistant Chief Accountant Office of Emerging Growth Companies Securities and Exchange Commission 450 Fifth Street N. |
|
| September 6, 2007 |
OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 32.A CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Marc D. Grodman, Chief Executive Officer of Bio-Reference Laboratories, Inc. (the “Company”), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: (a) the Quarterly Report on Form 10-Q of |
|
| September 6, 2007 |
Exhibit 31.A CHIEF EXECUTIVE OFFICER CERTIFICATION I, Marc D. Grodman, Chief Executive Officer of Bio-Reference Laboratories, Inc. (the “Company”) do hereby certify that: (1) I have reviewed this quarterly report on Form 10-Q of the Company for the quarterly period ended July 31, 2007; (2) Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit |
|
| September 6, 2007 |
Exhibit 32.B CERTIFICATION PURSUANT TO OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 32.B CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Sam Singer, Chief Financial Officer of Bio-Reference Laboratories, Inc. (the “Company”), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: (a) the Quarterly Report on Form 10-Q of the C |
|
| September 6, 2007 |
Exhibit 31.B CHIEF FINANCIAL OFFICER CERTIFICATION I, Sam Singer, Chief Financial Officer of Bio-Reference Laboratories, Inc. (the “Company”) do hereby certify that: (1) I have reviewed this quarterly report on Form 10-Q of the Company for the quarterly period ended July 31, 2007; (2) Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to s |
|
| September 6, 2007 |
SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| July 12, 2007 |
July 12 , 2007 Tia Jenkins- Mail Stop 3961 Senior Assistant Chief Accountant Office of Emerging Growth Companies Securities and Exchange Commission 450 Fifth Street N. |
|
| June 11, 2007 |
CHIEF FINANCIAL OFFICER CERTIFICATION Exhibit 31.B CHIEF FINANCIAL OFFICER CERTIFICATION I, Sam Singer, Chief Financial Officer of Bio-Reference Laboratories, Inc. (the “Company”) do hereby certify that: I have reviewed this quarterly report on Form 10-Q of the Company for the quarterly period ended April 30, 2007 Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a m |
